General Information of Drug (ID: DM7QUN0)

Drug Name
HQK-1001 Drug Info
Synonyms Sodium ST-20; Hematological disease therapeutic (oral), HemaQuest
Indication
Disease Entry ICD 11 Status REF
Beta thalassemia 3A50.2 Phase 2 [1]
Cross-matching ID
PubChem CID
53247304
CAS Number
CAS 3934-02-9
TTD Drug ID
DM7QUN0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Hemoglobin (HB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Voxelotor DMCS6M5 Sickle-cell disorder 3A51 Approved [3]
Iron DMAP8MV Anemia of prematurity Approved [4]
Iron Dextran DM5OY70 Iron-deficiency anemia 3A00 Approved [4]
PolyHeme DMV8EXG Blood forming organ disorder JB64.1 Phase 3 [5]
Efaproxyn DMX7BM4 Lung cancer 2C25.0 Phase 3 [6]
Hemoglobin raffimer DMMTL7V Anemia 3A00-3A9Z Phase 2/3 [7]
GBT021601 DMD3C21 Sickle-cell disorder 3A51 Phase 2/3 [8]
FBS-0701 DMR3952 Iron overload disease 5C64.10 Phase 2 [9]
5-hydroxymethyl-2-furfural DMPFVJB Anemia 3A00-3A9Z Phase 2 [10]
OXY-111A DMTH75R Cardiovascular disease BA00-BE2Z Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hemoglobin (HB) TTQO71U HBA_HUMAN Inducer [2]

References

1 A phase 2 trial of HQK-1001 in HbE-beta thalassemia demonstrates HbF induction and reduced anemia. Blood. 2014 Mar 20;123(12):1956-7.
2 A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
5 Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
6 Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
7 Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
8 GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.
9 A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
10 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.
11 Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71.